Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	3	OCT 19	BEILSTEIN updated with new compounds
NEWS	4	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	5	NOV 19	WPIX enhanced with XML display format
NEWS	6	NOV 30	ICSD reloaded with enhancements
NEWS	7	DEC 04	LINPADOCDB now available on STN
NEWS	8	DEC 14	BEILSTEIN pricing structure to change
NEWS	9	DEC 17	USPATOLD added to additional database clusters
NEWS	10	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	11	DEC 17	DGENE now includes more than 10 million sequences
NEWS	12	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	13	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	14	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS	15	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	16	JAN 02	STN pricing information for 2008 now available
NEWS	17	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	18	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	19	JAN 28	MARPAT searching enhanced
NEWS	20	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	21	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	22	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	23	FEB 08	STN Express, Version 8.3, now available
NEWS	24	FEB 20	PCI now available as a replacement to DPCI
NEWS	25	FEB 25	IFIREF reloaded with enhancements
NEWS	26	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	27	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	28	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	29	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	30	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS	31	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	32	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

```
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:25:57 ON 03 APR 2008

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 17:26:07 ON 03 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    2 APR 2008  HIGHEST RN 1011757-08-6
DICTIONARY FILE UPDATES:   2 APR 2008  HIGHEST RN 1011757-08-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10561051.str
```





chain nodes :
11 12 13 14
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
1-11 6-13 7-12 8-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9
exact/norm bonds :
1-2 1-6 1-11 2-3 3-4 4-5 5-6 6-13 7-12 8-14
exact bonds :
4-7 5-9 7-8 8-9
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:CLASS
12:CLASS 13:Atom 14:CLASS

L1   STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1   STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 17:26:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   128 TO ITERATE

100.0% PROCESSED   128 ITERATIONS   2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 1882 TO   3238
PROJECTED ANSWERS: 2 TO   124

L2   2 SEA SSS SAM L1

```
=> s l1 full
FULL SEARCH INITIATED 17:26:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     2591 TO ITERATE

100.0% PROCESSED     2591 ITERATIONS                                27 ANSWERS
SEARCH TIME: 00.00.01

L3           27 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     178.36     178.57

FILE 'CAPLUS' ENTERED AT 17:26:34 ON 03 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 3 Apr 2008  VOL 148 ISS 14
FILE LAST UPDATED: 2 Apr 2008  (20080402/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 full
L4           10 L3

=> d ibib abs hitstr tot
```

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:516682 CAPLUS
DOCUMENT NUMBER: 145:27972
TITLE: Process for palladium catalyzed C-N coupling
INVENTOR(S): Schlummer, Bjoern; Scholz, Ulrich; Smith, Ian
PATENT ASSIGNEE(S): Ucb, S.A., Belg.
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006056412	A1	20060601	WO 2005-EP12509	20051123
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
DE 102004056821	A1	20060601	DE 2004-102004056821	20041124
AU 2005308941	A1	20060601	AU 2005-308941	20051123
CA 2586440	A1	20060601	CA 2005-2586440	20051123
EP 1817313	A1	20070815	EP 2005-808296	20051123
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
IN 2007DN03451	A	20070831	IN 2007-DN3451	20070509
KR 2007086565	A	20070827	KR 2007-714254	20070622

PRIORITY APPLN. INFO.: DE 2004-102004056821A 20041124
DE 2004-102004056820A 20041124
WO 2005-EP12509 W 20051123

OTHER SOURCE(S): CASREACT 145:27972; MARPAT 145:27972
GI



I



II

AB The invention relates to a process for the preparation of thieno[2,3-b]pyridine derivs. I [wherein X = O, S, NH, or CH2; Y = O or S; Z and B = independently N or CH; R1-R3 = independently H, (pseudo)halo, OH, NO2, (un)substituted alkyl, alkoxy, aryl, etc.; R4 = H, (un)substituted alkyl, aryl, or arylalkyl; R = independently H, (pseudo)halo, OH, NO2, (un)substituted alkyl, alkoxy, aryl, etc.; n = 0-5] comprising coupling of

an aryl halide or an aryloxysulfonyl compound with an amine in the presence of palladium catalyst. For example, 3-amino-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-nitrile was reacted with 3-bromotoluene in the presence of tris(dibenzylideneacetone)palladium, a phosphorus ligand, and potassium phosphate to give II (87%). The process is useful for the formation of C-N bonds.

IT 639481-33-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(palladium catalyzed C-N coupling)

RN 639481-33-7 CAPLUS

CN Thieno[2,3-b]pyridine-2-carbonitrile, 3-amino-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:409526 CAPLUS
DOCUMENT NUMBER: 142:463710
TITLE: Preparation of thieno[2,3-b]pyridinone derivatives as kinase, especially p38 MAP kinase, inhibitors useful in the treatment of and/or prevention of immune or inflammatory disorders
INVENTOR(S): Alexander, Rikki Peter; Davis, Jeremy Martin; Hutchings, Martin Clive; Laing, Victoria Elizabeth; Trevitt, Graham Peter
PATENT ASSIGNEE(S): Celltech R & D Limited, UK
SOURCE: PCT Int. Appl., 181 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005042540	A1	20050512	WO 2004-GB4490		20041022
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004285752	A1	20050512	AU 2004-285752		20041022
CA 2540881	A1	20050512	CA 2004-2540881		20041022
EP 1680429	A1	20060719	EP 2004-769004		20041022
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
JP 2007509123	T	20070412	JP 2006-536178		20041022
US 20070078131	A1	20070405	US 2006-576731		20060420
PRIORITY APPLN. INFO.:			GB 2003-24902	A	20031024
			GB 2003-29490	A	20031219
			GB 2004-2918	A	20040210
			GB 2004-16934	A	20040729
			WO 2004-GB4490	W	20041022

OTHER SOURCE(S): MARPAT 142:463710
GI



I



II

AB Title compds. I [wherein R1 = (un)substituted (C3-7 cycloalkyl)methyl, hetero/aryl; R2 = H, NO2, CN, CO2H and derivs., NH2 and derivs., etc.; R3 = (un)substituted hetero/aryl; and their pharmaceutically acceptable salts] were prepared as p38 MAP kinase inhibitors for treating and/or preventing immune or inflammatory disorders. For example, II was prepared by reacting Et 3-bromo-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate (preparation given) with 3-methylbenzaldehyde and oxidation with MnO2.

I are potent inhibitors of p38 MAP kinase (IC50 around 2 μM and below), especially p38α kinase.

IT 639481-33-7P, 3-Amino-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile 639481-35-9P, 3-Amino-7-(2-chlorophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile 817177-56-3P, 3-Amino-2-nitro-7-phenylthieno[2,3-b]pyridin-6(7H)-one 851748-38-4P, 3-Amino-7-(2-chlorophenyl)-2-nitrothieno[2,3-b]pyridin-6(7H)-one 851748-57-7P, 3-Amino-7-(2-fluorophenyl)-2-nitrothieno[2,3-b]pyridin-6(7H)-one 851748-69-1P, 3-Amino-7-(6-chloropyridin-3-yl)-2-nitrothieno[2,3-b]pyridin-6(7H)-one 851749-70-7P, 3-Amino-7-(2,6-difluorophenyl)-2-nitrothieno[2,3-b]pyridin-6(7H)-one 851749-97-8P, 3-Amino-7-(4-methylphenyl)-2-nitrothieno[2,3-b]pyridin-6(7H)-one 851750-11-3P, 3-Amino-7-(4-fluorophenyl)-2-nitrothieno[2,3-b]pyridin-6(7H)-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of thienopyridinones as p38 MAP kinase inhibitors useful in the treatment of and/or prevention of immune or inflammatory disorders)

RN 639481-33-7 CAPLUS

CN Thieno[2,3-b]pyridine-2-carbonitrile, 3-amino-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639481-35-9 CAPLUS
CN Thieno[2,3-b]pyridine-2-carbonitrile, 3-amino-7-(2-chlorophenyl)-6,7-dihydro-6-oxo- (CA INDEX NAME)



RN 817177-56-3 CAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-amino-2-nitro-7-phenyl- (CA INDEX NAME)



RN 851748-38-4 CAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-amino-7-(2-chlorophenyl)-2-nitro- (CA INDEX NAME)



RN 851748-57-7 CAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-amino-7-(2-fluorophenyl)-2-nitro- (CA INDEX NAME)



RN 851748-69-1 CAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-amino-7-(6-chloro-3-pyridinyl)-2-nitro- (CA INDEX NAME)



RN 851749-70-7 CAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-amino-7-(2,6-difluorophenyl)-2-nitro- (CA INDEX NAME)



RN 851749-97-8 CAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-amino-7-(4-methylphenyl)-2-nitro- (CA INDEX NAME)



RN 851750-11-3 CAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-amino-7-(4-fluorophenyl)-2-nitro- (CA INDEX NAME)



IT 851748-71-5P, 3-Amino-7-(6-ethoxypyridin-3-yl)-2-nitrothieno[2,3-b]pyridin-6(7H)-one
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of thienopyridinones as p38 MAP kinase inhibitors useful in the treatment of and/or prevention of immune or inflammatory disorders)
RN 851748-71-5 CAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-amino-7-(6-ethoxy-3-pyridinyl)-2-nitro- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:1154722 CAPLUS
DOCUMENT NUMBER: 142:93797
TITLE: Process for preparing 3-aminothienopyridone derivatives and their applications to the synthesis of p38 MAP kinase inhibitors
INVENTOR(S): Evans, Graham Robert; Smith, Ian Harold; Tremayne, Neil; Jones, Leighton; Langston, Marianne
PATENT ASSIGNEE(S): Celltech R & D Limited, UK
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113349	A1	20041229	WO 2004-GB2680	20040618
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004249507	A1	20041229	AU 2004-249507	20040618
CA 2528927	A1	20041229	CA 2004-2528927	20040618
EP 1638980	A1	20060329	EP 2004-743031	20040618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007516163	T	20070621	JP 2006-516465	20040618
US 20070191608	A1	20070816	US 2006-561051	20060608

PRIORITY APPLN. INFO.: GB 2003-14493 A 20030620
GB 2003-29471 A 20031219
WO 2004-GB2680 W 20040618

OTHER SOURCE(S): MARPAT 142:93797
GI



I



II



III



IV



V

AB This invention provides a class of 3-amino-7H-thieno[2,3-b]pyridin-6-one derivs. I [wherein R = cyano, NO2, CO2Alk2, C(O)alkyl, CONHHet2; Alk2 = (un)substituted alkyl or aryl; Het2 = (un)substituted 4/5/6-membered heterocycloalkyl; R1 = (un)substituted (hetero)aryl or (hetero)cycloalkyl; R2, R3 = H or a hydrogen atom precursor, or salts, solvates, hydrates, protected derivs. and N-oxides thereof], a process for their prepns., and the use thereof as intermediates in the manufacture of certain p38 MAP kinase inhibitors. For example, 2-cyano-N-phenylthioacetamide was treated with N,N-dimethyluracil to give crude thiolate II containing about 20% ethanol, which was directly refluxed with chloroacetonitrile in acetonitrile for 2 h to afford amine III. This compound underwent diazotization and subsequent halide displacement with tert-butylnitrite and CuBr2, leading to bromide IV. Pd-catalyzed N-alkylation of III with bromobenzene or amination of IV with aniline yielded V. Conversion of this product to the corresponding carboxamide was realized by the hydrolysis of the cyano group in the presence of NaOH-H2O-Ethanol system.

IT 639481-33-7P, 3-Amino-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile 639481-34-8P, 3-Amino-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylic acid ethyl ester 639481-35-9P, 3-Amino-7-(2-chlorophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile 639481-42-8P, 3-Amino-7-cyclopropyl-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile 817177-51-8P, 3-Amino-7-phenyl-2-[(pyrrolidin-1-yl)carbonyl]-7H-thieno[2,3-b]pyridin-6-one 817177-53-0P 817177-55-2P, (S)-3-Amino-2-[(2-hydroxymethylpyrrolidin-1-yl)carbonyl]-7-phenyl-7H-thieno[2,3-b]pyridin-6-one 817177-56-3P, 3-Amino-2-nitro-7-phenyl-7H-thieno[2,3-b]pyridin-6-one 817177-58-5P, 3-Amino-2-(4-ethylpiperazin-1-ylcarbonyl)-7-phenyl-7H-thieno[2,3-b]pyridin-6-one
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for preparing 3-aminothienopyridone derivs. and their applications to the synthesis of p38 MAP kinase inhibitors)

RN 639481-33-7 CAPLUS

CN Thieno[2,3-b]pyridine-2-carbonitrile, 3-amino-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639481-34-8 CAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-amino-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639481-35-9 CAPLUS
CN Thieno[2,3-b]pyridine-2-carbonitrile, 3-amino-7-(2-chlorophenyl)-6,7-dihydro-6-oxo- (CA INDEX NAME)



RN 639481-42-8 CAPLUS
CN Thieno[2,3-b]pyridine-2-carbonitrile, 3-amino-7-cyclopropyl-6,7-dihydro-6-oxo- (CA INDEX NAME)



RN 817177-51-8 CAPLUS
CN Pyrrolidine, 1-[(3-amino-6,7-dihydro-6-oxo-7-phenylthieno[2,3-b]pyridin-2-yl)carbonyl]- (9CI) (CA INDEX NAME)



RN 817177-53-0 CAPLUS
CN Pyrrolidine, 1-[(3-amino-6,7-dihydro-6-oxo-7-phenylthieno[2,3-b]pyridin-2-yl)carbonyl]-3-[(tetrahydro-2H-pyran-2-yl)oxy]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 817177-55-2 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[(3-amino-6,7-dihydro-6-oxo-7-phenylthieno[2,3-b]pyridin-2-yl)carbonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 817177-56-3 CAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 3-amino-2-nitro-7-phenyl- (CA INDEX NAME)



RN 817177-58-5 CAPLUS
CN Piperazine, 1-[(3-amino-6,7-dihydro-6-oxo-7-phenylthieno[2,3-b]pyridin-2-yl)carbonyl]-4-ethyl- (9CI) (CA INDEX NAME)



IT 639481-38-2P, 3-Amino-7-(4-methylphenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile 639481-44-0P, 3-Amino-7-(2-methylphenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(process for preparing 3-aminothienopyridone derivs. and their applications to the synthesis of p38 MAP kinase inhibitors)

RN 639481-38-2 CAPLUS
CN Thieno[2,3-b]pyridine-2-carbonitrile, 3-amino-6,7-dihydro-7-(4-methylphenyl)-6-oxo- (CA INDEX NAME)



RN 639481-44-0 CAPLUS
CN Thieno[2,3-b]pyridine-2-carbonitrile, 3-amino-6,7-dihydro-7-(2-methylphenyl)-6-oxo- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:1154721 CAPLUS
DOCUMENT NUMBER: 142:93796
TITLE: Preparation of thienopyridone derivatives as p38 MAPK inhibitors
INVENTOR(S): Brookings, Daniel Christopher; Davis, Jeremy Martin; Langham, Barry John
PATENT ASSIGNEE(S): Celltech R & D Limited, UK
SOURCE: PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113348	A1	20041229	WO 2004-GB2644	20040618
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004249498	A1	20041229	AU 2004-249498	20040618
CA 2528603	A1	20041229	CA 2004-2528603	20040618
EP 1638979	A1	20060329	EP 2004-742997	20040618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
JP 2007516162	T	20070621	JP 2006-516453	20040618
US 20060247269	A1	20061102	US 2006-561050	20060629
PRIORITY APPLN. INFO.:			GB 2003-14490 A	20030620
			GB 2003-29495 A	20031219
			WO 2004-GB2644 W	20040618

OTHER SOURCE(S): MARPAT 142:93796
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein X = covalent bond, NH or N(alkyl); Y = C(O) or S(O)2; A = (CH2)q; B = (CH2)m; n = 0 or 1; m = 1-3; p = 0-4; q = 0-2; R = (un)substituted OH, alkoxy or amino; L = O, S, S(O), S(O)2 or CH2, CHR or CR2, NH or N(alkyl); ALK1 = alkylene; Cy1 = (un)substituted (hetero)cycle or (hetero)aryl; Ar = (un)substituted (hetero)aryl; or salts, solvates, hydrates and N-oxides thereof] were prepared as p38 MAPK inhibitors. For example, II was synthesized in several steps from Et 3-bromo-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate (preparation given), via amination with 2,4-difluoroaniline, ester hydrolysis, carboxy group activation with pentafluorophenol and coupling with cis-2-aminocyclopentanol hydrochloride. Example compds. had IC50 values of around 1 μM and below for human p38α kinase. Therefore, I and pharmaceutical compns. thereof are useful for the treatment and/or prevention of immune or inflammatory disorders.

IT 816464-43-4P, 9H-Fluoren-9-ylmethyl 4-[(3-amino-6-oxo-7-phenyl-6,7-

dihydrothieno[2,3-b]pyridin-2-yl)carbonyl]piperidine-1-carboxylate
816464-48-9P, Benzyl 4-[(3-amino-6-oxo-7-phenyl-6,7-
dihydrothieno[2,3-b]pyridin-2-yl)carbonyl]piperidine-1-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of thienopyridone derivs. as p38 MAPK inhibitors)

RN 816464-43-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(3-amino-6,7-dihydro-6-oxo-7-
phenylthieno[2,3-b]pyridin-2-yl)carbonyl]-, 9H-fluoren-9-ylmethyl ester
(CA INDEX NAME)



RN 816464-48-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(3-amino-6,7-dihydro-6-oxo-7-
phenylthieno[2,3-b]pyridin-2-yl)carbonyl]-, phenylmethyl ester (CA INDEX
NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:1154720 CAPLUS
DOCUMENT NUMBER: 142:93795
TITLE: Preparation of thienopyridone derivatives as p38α kinase inhibitors
INVENTOR(S): Brookings, Daniel Christopher; Davis, Jeremy Martin; Langham, Barry John
PATENT ASSIGNEE(S): Celltech R & D Limited, UK
SOURCE: PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004113347	A1	20041229	WO 2004-GB2621		20040618
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004249495	A1	20041229	AU 2004-249495		20040618
CA 2528602	A1	20041229	CA 2004-2528602		20040618
EP 1641804	A1	20060405	EP 2004-742976		20040618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
BR 2004010653	A	20060704	BR 2004-10653		20040618
CN 1809575	A	20060726	CN 2004-80017320		20040618
JP 2007516161	T	20070621	JP 2006-516443		20040618
MX 2005PA13227	A	20060309	MX 2005-PA13227		20051206
IN 2005DN05823	A	20080201	IN 2005-DN5823		20051214
NO 2006000279	A	20060320	NO 2006-279		20060119
US 20070099894	A1	20070503	US 2006-561052		20061010
PRIORITY APPLN. INFO.:			GB 2003-14492	A	20030620
			GB 2003-29485	A	20031219
			WO 2004-GB2621	W	20040618

OTHER SOURCE(S): CASREACT 142:93795; MARPAT 142:93795
GI



AB Title compds. I [Y = linking group CO, SO2; n = 0-1; m, p = 1-4; R1 = OH, alkylene-OH, alkoxy, etc.; Alk1 = alkylene; Cy1 = cycloaliph., aromatic, heteroarom., etc.; Ar = (un)substituted (hetero)aromatic, etc.] are prepared For instance, 3-Bromo-7-phenyl-2-[[(2R)-2-[((tetrahydro-2H-pyran-2-yl)oxy)methyl]pyrrolidin-1-yl]carbonyl]thieno[2,3-b]pyridin-6(7H)-one (preparation given) is coupled to 2,4-difluoroaniline (PhMe, Cs2CO3, BINAP, Pd2(dba)3, reflux 48 h) and the resulting product deprotected with HCl to give II. All compds. inhibit p38 kinase with IC50 of 1 μM or less. I are useful for the treatment and/or prevention of immune or inflammatory disorders.

IT 639481-35-9P, 3-Amino-7-(2-chlorophenyl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-2-carbonitrile
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thienopyridone derivs. as p38α kinase inhibitors)

RN 639481-35-9 CAPLUS

CN Thieno[2,3-b]pyridine-2-carbonitrile, 3-amino-7-(2-chlorophenyl)-6,7-dihydro-6-oxo- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:143162 CAPLUS
DOCUMENT NUMBER: 140:181432
TITLE: Preparation of bicyclic heteroaromatic compounds as p38 kinase inhibitors
INVENTOR(S): Brookings, Daniel Christopher; Davis, Jeremy Martin; Langham, Barry John
PATENT ASSIGNEE(S): Celltech R & D Limited, UK
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014920	A1	20040219	WO 2003-GB3501	20030811
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2495518	A1	20040219	CA 2003-2495518	20030811
AU 2003252990	A1	20040225	AU 2003-252990	20030811
EP 1539769	A1	20050615	EP 2003-784288	20030811
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005537300	T	20051208	JP 2004-527055	20030811
US 20060025428	A1	20060202	US 2005-524199	20050728
PRIORITY APPLN. INFO.:			GB 2002-18800 A	20020813
			WO 2003-GB3501 W	20030811

OTHER SOURCE(S): MARPAT 140:181432
GI



I



II

AB Title compds. I [A = N, (un)substituted CH, dashed line is a double bond; A = (un)substituted NH, CH2, dashed line is a single bond; X = O, S, (un)substituted NH, S(O), SO2; Y = N, (un)substituted CH; Alk = (un)substituted aliphatic, heteroaliph.; n = 0, 1; Ar = (un)substituted aromatic, heteroarom.; L = atom, alkylene, heteroalkylene; L1 = bond, linker atom, linker group; Cy = H, (un)substituted cycloaliph, polycycloaliph., heterocyclic, polyheterocyclic, aromatic, heteroarom.; R = H, CN, (un)substituted alkyl,CO2H, CONH2], especially 6-oxo-6,7-dihydrothieno[2,3-

b]pyridine derivs., which are inhibitors of p38 kinase of use in the treatment and/or prevention of immune or inflammatory disorders (no data) were prepared Thus, II [R1 = NHCH2Ph, r2 = Ph] was prepared from 2-chloronicotinonitrile and HSCH2CO2Et via II [R1 = Br, R2 = H] by treatment with PhB(OH)2 and PhCH2NH2.

IT 639481-33-7P 639481-34-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of bicyclic heteroarom. compds. as p38 kinase inhibitors)

RN 639481-33-7 CAPLUS
CN Thieno[2,3-b]pyridine-2-carbonitrile, 3-amino-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639481-34-8 CAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-amino-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:2888 CAPLUS
DOCUMENT NUMBER: 140:59658
TITLE: Preparation of arylamine substituted bicyclic hetero-aromatic compounds as p38 kinase inhibitors
INVENTOR(S): Brookings, Daniel Christopher; Davis, Jeremy Martin; Langham, Barry John
PATENT ASSIGNEE(S): Celltech R & D Limited, UK
SOURCE: PCT Int. Appl., 174 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000846	A1	20031231	WO 2003-GB2667	20030620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2487718	A1	20031231	CA 2003-2487718	20030620
AU 2003253087	A1	20040106	AU 2003-253087	20030620
BR 2003011842	A	20050315	BR 2003-11842	20030620
EP 1551848	A1	20050713	EP 2003-760802	20030620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1671715	A	20050921	CN 2003-818371	20030620
JP 2005530838	T	20051013	JP 2004-515043	20030620
NZ 537740	A	20060331	NZ 2003-537740	20030620
MX 2004PA12746	A	20050323	MX 2004-PA12746	20041215
NO 2005000306	A	20050316	NO 2005-306	20050119
ZA 2005000524	A	20060830	ZA 2005-524	20050119
US 20060004025	A1	20060105	US 2005-518725	20050526

PRIORITY APPLN. INFO.: GB 2002-14268 A 20020620
WO 2003-GB2667 W 20030620

OTHER SOURCE(S): MARPAT 140:59658
GI



I

AB Bicyclic heteroarom. derivs. I; where the dashed line joining A and C(Ra) is present and represents a bond and A is a -N= atom or a -C(Rb)= group, or the dashed line is absent and A is a -N(Rb)-, or -C(Rb)(Rc)- group; X is an -O-, -S- or substituted nitrogen atom or a -S(O)-, -S(O2)- or -NH-

group; Y is a nitrogen or substituted carbon atom or a -CH = group; n is zero or the integer 1; Alk1 is an optionally substituted aliphatic or hetero-aliphatic chain L1 is a covalent bond or a linker atom or group; Cy1 is a hydrogen atom or an optionally substituted cyclo-aliphatic, poly-cyclo-aliphatic, hetero-cyclo-aliphatic, poly-hetero-cyclo-aliphatic, aromatic or hetero-aromatic group; Ar is an optionally substituted aromatic or heteroarom. group; and the remaining substituents are defined in the specification. The compds. are potent and selective inhibitors of p38 kinase and are of use in the prophylaxis and treatment of immune or inflammatory disorders. Thus, 3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-N-pyrrolidin-3-yl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide was prepared as as p38 kinase inhibitor. In the p38 inhibitor assays described above compds. of the invention have IC50 values of around 1 μM and below. The compds. of the invention are clearly potent inhibitors of p38 kinase, especially p38α kinase.

IT 639481-33-7P 639481-34-8P 639481-35-9P
639481-38-2P 639481-42-8P 639481-44-0P
639481-75-7P 639481-76-8P 639482-12-5P
639482-14-7P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylamine substituted bicyclic hetero-aromatic compds. as p38 kinase inhibitors)

RN 639481-33-7 CAPLUS
CN Thieno[2,3-b]pyridine-2-carbonitrile, 3-amino-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



RN 639481-34-8 CAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-amino-6,7-dihydro-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639481-35-9 CAPLUS
CN Thieno[2,3-b]pyridine-2-carbonitrile, 3-amino-7-(2-chlorophenyl)-6,7-dihydro-6-oxo- (CA INDEX NAME)



RN 639481-38-2 CAPLUS
CN Thieno[2,3-b]pyridine-2-carbonitrile, 3-amino-6,7-dihydro-7-(4-methylphenyl)-6-oxo- (CA INDEX NAME)



RN 639481-42-8 CAPLUS
CN Thieno[2,3-b]pyridine-2-carbonitrile, 3-amino-7-cyclopropyl-6,7-dihydro-6-oxo- (CA INDEX NAME)



RN 639481-44-0 CAPLUS
CN Thieno[2,3-b]pyridine-2-carbonitrile, 3-amino-6,7-dihydro-7-(2-methylphenyl)-6-oxo- (CA INDEX NAME)



RN 639481-75-7 CAPLUS

CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-amino-5-bromo-6,7-dihydro-4-methyl-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639481-76-8 CAPLUS
CN Thieno[2,3-b]pyridine-2-carboxylic acid, 3-amino-6,7-dihydro-4-methyl-6-oxo-7-phenyl-, ethyl ester (CA INDEX NAME)



RN 639482-12-5 CAPLUS
CN Thieno[2,3-b]pyridin-6(7H)-one, 2-acetyl-3-amino-7-phenyl- (CA INDEX NAME)



RN 639482-14-7 CAPLUS
CN Thieno[2,3-b]pyridine-2-carbonitrile, 3-amino-6,7-dihydro-6-oxo-7-(3-pyridinyl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:29695 CAPLUS
DOCUMENT NUMBER: 136:325480
TITLE: Novel synthesis of thiazole, coumarin, pyridine, thiophene and thieno[2,3-b]pyridine derivatives
AUTHOR(S): El-Taweel, F. M. A.; Elagamey, A. A.; El-Kenawy, A. A.; Waly, M. A.
CORPORATE SOURCE: Department of Chemistry, Faculty of Science, Mansoura University, New Damietta, Egypt
SOURCE: Phosphorus, Sulfur and Silicon and the Related Elements (2001), 176, 215-225
CODEN: PSSLEC; ISSN: 1042-6507
PUBLISHER: Gordon & Breach Science Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 136:325480

AB Several new thiazole, coumarin, pyridine, thiophene, and thienopyridines were prepared from 4-chloroacetylantipyrine and activated nitriles as starting materials.

IT 413570-88-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of thiazole, coumarin, pyridine, thiophene, and thieno[2,3-b]pyridine derivs.)

RN 413570-88-4 CAPLUS
CN Thieno[2,3-b]pyridine-5-carbonitrile, 3,4-diamino-2-[(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)carbonyl]-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:531099 CAPLUS
DOCUMENT NUMBER: 117:131099
TITLE: One-pot synthesis of polyfunctionally substituted thiophenes: thieno[2,3-b]pyridine and thieno[3,4-d]pyridazine derivatives
AUTHOR(S): Mohareb, Rafat Milad
CORPORATE SOURCE: Fac. Sci., Cairo Univ., Giza, Egypt
SOURCE: Gazzetta Chimica Italiana (1992), 122(4), 147-50
CODEN: GCITA9; ISSN: 0016-5603
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB The enaminonitriles EtO2CCH2C(NH2):C(CN)CO2Et), NCCH2C(NH2):C(CN)2, and MeC(:NH)CH2CN treated with Ph isothiocyanate followed by cyclization with PHCH2COBr gave the thiophene I, the thieno[2,3-b]pyridine II and the thiophene III, resp. The reactivity of the reaction products toward different reagents to form heterocyclic and fused heterocyclic ring systems was confirmed.

IT 143208-39-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 143208-39-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carbonitrile, 3,4-diamino-2-benzoyl-6,7-dihydro-6-oxo-7-phenyl- (CA INDEX NAME)



L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:407844 CAPLUS
DOCUMENT NUMBER: 117:7844
TITLE: Novel synthesis of 4-(coumarin-3-yl)-1,3-thiazole, 2-(coumarin-3-carbonyl)thieno[2,3-b]pyridine, and 2-(coumarin-3-carbonyl)thiophene derivatives
AUTHOR(S): Mohareb, Rafat Milad; Shams, Hoda Zaki; Aziz, Suzan Ibrahim
CORPORATE SOURCE: Fac. Sci., Cairo Univ., Giza, Egypt
SOURCE: Journal of Chemical Research, Synopses (1992), (5), 154-5
CODEN: JRPSDC; ISSN: 0308-2342
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 117:7844
GI



I



II



III

AB The active methylene reagents CH2RR1 (R = CN, R1 = CO2Et; R = COMe, R1 = COMe, CO2Et, CONHPh) react with PhNCS followed by cyclization with I bromoacetylcoumarin to afford the thiazole derivs. II, whereas CH2RR1(R = CN, R1 = CONH2, CSNH2, CONHPh) react with the same reagents at both low and high temps. to afford III and the thiophene derivs.

IT 141633-02-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 141633-02-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carbonitrile, 3,4-diamino-6,7-dihydro-6-oxo-2-[(2-oxo-2H-1-benzopyran-3-yl)carbonyl]-7-phenyl- (CA INDEX NAME)



```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      58.34     236.91

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -8.00      -8.00

STN INTERNATIONAL LOGOFF AT 17:31:11 ON 03 APR 2008
```